PDCD1 and neoplasm: The results showed that the combination of intratumoral injections of rAd-p53 and intraperitoneal injections of anti-PD-1 antibody demonstrated the highest tumor growth inhibitory effects and the longest survival periods among the all treatment groups in both tumor models (Figs. 5, 6).